The Development of FVIII Inhibitors in Relation to<i>IL10</i>Gene Polymorphism in Hemophilia A Egyptian Pediatric Patients

Sadek, Hoda; Youssry, Ilham; Ibrahim, Nihal Salah; Abou-Elalla, Amany A.; G, Atef; Mousa, Somaia Mohammed

doi:10.1080/15513815.2017.1281363

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One recent study from Egypt reported a 22% prevalence of FVIII inhibitors in patients with severe HA, 12 while another reported a prevalence of 12% in moderate to severe disease. 13 In turkey, a large recent study, including 657 patients with severe HA, found 15.8% to be positive for inhibitors. 14 Other reports also indicated an overall inhibitor prevalence of around 14% and a prevalence of 16.7% in patients with severe disease.…”

Section: Where Do We Stand?mentioning

confidence: 98%

“…Data from non‐Western countries are mainly based on cross‐sectional or retrospective studies. One recent study from Egypt reported a 22% prevalence of FVIII inhibitors in patients with severe HA, 12 while another reported a prevalence of 12% in moderate to severe disease 13 . In turkey, a large recent study, including 657 patients with severe HA, found 15.8% to be positive for inhibitors 14 .…”

Section: Where Do We Stand?mentioning

confidence: 99%

See 1 more Smart Citation

Management of haemophilia A with inhibitors: A regional cross‐talk

et al. 2022

View full text Add to dashboard Cite

Introduction The development of inhibitors with factor VIII (FVIII) replacement therapy is one of the most common and challenging complications of haemophilia A (HA) treatment, jeopardising treatment efficacy and predisposing patients to high risks of morbidity and mortality. The management of patients with inhibitors is particularly challenging in countries where resources are limited. Aim To provide a comprehensive summary of the management of HA with inhibitors while focusing on differences in practice between Western and non‐Western countries and how resource scarcity can impact HA management, leading to suboptimal outcomes in patients with inhibitors. Methods Summary of key evidence and regional expert opinion. Results We address, particularly, the diagnosis of and testing for inhibitors, as well as the epidemiology of inhibitors, including incidence, prevalence and disease burden. Secondly, we provide an overview of the current treatment landscape in HA with inhibitors regarding the eradication of inhibitors with immune tolerance induction and the treatment and prevention of bleeding with bypassing agents, non‐factor replacement agents and other experimental therapies. This is complemented with insights from the authors around the applicability of, and challenges associated with, such therapies in their settings of practice. Conclusions We conclude by proposing some key steps towards bridging the gaps in the management of HA with inhibitors in resource‐limited countries, including: (1) the collection of quality data that can inform healthcare reforms and policies; (2) improving disease knowledge among healthcare practitioners and patients with the aim of standardising disease management across centres and (3) working towards promoting equal access to HA care and therapies for everyone.

show abstract

Section: Where Do We Stand?mentioning

confidence: 98%

Section: Where Do We Stand?mentioning

confidence: 99%